New national surveillance data announced at the UK Health Security Agency (UKHSA) annual conference has demonstrated an increase in antibiotic resistant infections and associated deaths in England.

GlaxoSmithKline has announced a new $2.2bn deal with US biotech company Alector to co-develop monoclonal antibodies for a number of neurodegenerative diseases. The focus of the deal is two ...

Researchers have discovered that the novel coronavirus – which causes the respiratory disease COVID-19 – remains stable on surfaces for several hours to days. The new study, undertaken by US National ...

Publicis Life Brands Resolute (PLBR) has named a former GlaxoSmithKline (GSK) communications director as its new head of planning. Sian Dodwell, who was director of branding and communications in the ...

Alcohol dependent patients in England are set to have access to a new pill to help control their drinking problem. Health guidance body the National Institute for Health and Care Excellence (NICE) ...

The US government has announced the ten drugs selected for the first round of pricing negotiations under President Biden’s Inflation Reduction Act (IRA). The IRA allows Medicare, the government health ...

Phase 3 data shows the long-acting antibody combination produces a 77% reduction in the risk of developing symptomatic COVID-19 AstraZeneca has submitted a request to the US Food and Drug ...

Gilead and EVOQ Therapeutics (EVOQ) have entered into a collaboration and licensing agreement aimed at advancing immunotherapies for the treatment of rheumatoid arthritis (RA) and lupus. Under the ...

Novo Nordisk and Echosens, a high-technology company specialising in liver diagnostics, have collaborated to advance early diagnosis of non-alcoholic steatohepatitis (NASH). The partnership aims to ...

Ipsen’s cabozantinib has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for patients with previously treated advanced hepatocellular carcinoma (HCC).

World Hepatitis Day takes place today, with this year’s theme, ‘I can’t wait’, highlighting the need to accelerate the fight against viral hepatitis to reach the 2030 elimination target. The campaign, ...

AstraZeneca continued its promised return to growth in the fourth quarter as its recovery from patent losses continues, with cancer drugs leading the charge once again. Sales rose 5% to $5.77bn in the ...